Related Experiment Video
Updated: Jul 27, 2026
13:33
Infinium Assay for Large-scale SNP Genotyping Applications
Published on: November 19, 2013
Human genome project: pharmacogenomics and drug development
N K Ganguly1, R Bano, S D Seth
1Indian Council of Medical Research, New Delhi.
Indian Journal of Experimental Biology
|March 9, 2002
Summary
Pharmacogenomics uses genetic variation to tailor drug treatments, improving efficacy and safety. Understanding individual genetic makeup enhances drug discovery and personalized medicine approaches.
Area of Science:
- Genomics
- Pharmacogenomics
- Personalized Medicine
Background:
- The human genome has been fully deciphered, opening avenues for custom drug treatments.
- Understanding genetic variations is crucial for predicting individual responses to therapeutics.
- Pharmacogenomics studies the link between genetics and drug response.
Purpose of the Study:
- To explore the implications of genomics and pharmacogenomics in clinical research and medicine.
- To highlight the role of genetic variation in personalized drug therapies.
- To discuss the discovery of single nucleotide polymorphisms (SNPs) and their impact.
Main Methods:
- Analyzing human genome sequence information.
- Identifying single nucleotide polymorphisms (SNPs).
- Correlating genetic makeup with drug disposition and effects.
Main Results:
- Discovery of numerous human polymorphisms (SNPs).
- Enabling the development of personalized drug therapies.
- Identifying patient subgroups likely to benefit from specific drugs.
Conclusions:
- Pharmacogenomics enhances drug discovery and provides a scientific basis for patient-specific treatments.
- Personalized medicine, guided by genetic insights, promises improved therapeutic outcomes.
- The rise of pharmacogenomics necessitates addressing ethical and legal considerations in research and clinical practice.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...